Skip to main content
Glama

Mydisease

by io.github.pipeworx-io

Entity Profile

entity_profile
Read-onlyIdempotent

"Tell me about X" / "research Acme" / "brief me on Tesla" / "what does Apple do" / "company profile for Microsoft" / "give me the rundown on NVDA" / "everything you know about $TICKER" — full cross-source profile of a US public company in ONE parallel call. ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view. Fans out across SEC EDGAR, XBRL, USPTO patents, federal contracts (USAspending), FDA-licensed biologics (Purple Book), H-1B hiring (DOL LCA), news and GLEIF, and returns: cik + company_name (+ resolved_from/resolved_to when value was a name); recent_filings (up to 5 with pipeworx://edgar/company/{cik}/filings/{accession} URIs); fundamentals (LATEST 10-K Revenues + NetIncomeLoss + Cash, sorted period_end DESC); patents (USPTO PatentsView API sunset May 2025 — soft-fails until reactivated); federal_contracts (USAspending awards where the company is the recipient); fda_products (FDA-licensed biologics — vaccines, cell/gene therapies — from the Purple Book; a company with only small-molecule/generic drugs will show none here, that is expected, not a failure); hiring (H-1B sponsorship volume + salary range from DOL LCA filings); recent news mentions via GDELT→GNews fallback; LEI via GLEIF. sources_used / sources_failed say which of these actually returned data for THIS company — an empty section is a real "no data", not a bug. Pass a ticker ("AAPL"), zero-padded CIK ("0000320193"), OR a company name ("Moderna") — names now resolve via SEC EDGAR's company-name match; a private company (no CIK/ticker) returns resolved:false with an explicit notes line, not a bare failure. type accepts "company" or "ticker" interchangeably — both take the same value shapes above.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYes"company" or "ticker" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon.
valueYesTicker (e.g., "AAPL"), zero-padded CIK (e.g., "0000320193"), or company name (e.g., "Moderna") — names resolve via SEC EDGAR company-name match.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed3 schema fields changed
    • changedInput schema / properties / type / description
      Previous value: -"Entity type. Only \"company\" supported today; person/place coming soon."New value: +"\"company\" or \"ticker\" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon."
    • changedInput schema / properties / type / enum
      Previous value: -[
-  "company"
-]New value: +[
+  "company",
+  "ticker"
+]
    • changedInput schema / properties / value / description
      Previous value: -"Ticker (e.g., \"AAPL\") or zero-padded CIK (e.g., \"0000320193\"). Names not supported — use resolve_entity first if you only have a name."New value: +"Ticker (e.g., \"AAPL\"), zero-padded CIK (e.g., \"0000320193\"), or company name (e.g., \"Moderna\") — names resolve via SEC EDGAR company-name match."
  2. First observed

TDQS

A4.3/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

The description adds rich behavior beyond the readOnly/openWorld/idempotent annotations: it explains the cross-source fan-out, GDELT→GNews fallback, `sources_used`/`sources_failed` semantics, and edge cases like 'an empty section is a real "no data", not a bug' and 'a private company returns resolved:false with an explicit notes line.' This is exactly the kind of contextual disclosure the annotations do not cover.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long, but it is front-loaded with purpose and usage signals before enumerating sources and return fields. The dense parentheticals are justified by the tool's complexity, and each clause conveys operational instructions. It could be better organized, but no sentence is filler.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description carries the full burden of return-value disclosure. It lists all expected sections (cik, company_name, recent_filings, fundamentals, patents, federal_contracts, fda_products, hiring, news, LEI) and explains failure semantics, fallback behavior, and input edge cases. There is no major missing piece an agent would need to guess.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, so the baseline is 3. The description adds meaningful value by clarifying that `type` is interchangeable ('both are accepted and behave identically') and by providing concrete examples (AAPL, 0000320193, Moderna). This goes beyond the schema without being necessary to understand the parameters.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose4/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with concrete trigger phrases and states the core function: 'full cross-source profile of a US public company in ONE parallel call.' It distinguishes itself from chaining single-pack SEC/XBRL/news lookups, but it never names adjacent sibling tools like deep_research or compare_entities, so differentiation is partial.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly tells the agent when to prefer this tool: 'ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view.' It also gives user-phrasing examples. It does not state when not to use it or how it contrasts with specific sibling tools, so it stops short of a 5.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Mydisease toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.9/5.0
Disambiguation2/5

Multiple research/query entry points overlap heavily: ask_pipeworx and ask_pipeworx_beta are currently identical, ask_pipeworx_grounded and deep_research sit on the same routing core, and validate_claim/bet_research/entity_profile all wrap lookup-and-analyze behavior. The detailed descriptions help within specialized clusters, but the central ask_pipeworx family alone creates real selection ambiguity.

Naming Consistency3/5

All names are lower_snake_case and several families are consistent (ask_pipeworx_*, polymarket_*, remember/recall/forget), but the overall set mixes bare verbs, nouns, and verb_noun composites with no global pattern (disease, metadata, query, entity_profile, generate_llms_txt, validate_claim). It is readable but not predictable across the full 34-tool surface.

Tool Count2/5

34 tools is over the 25+ threshold and the set bundles several distinct domains—disease ontology, Pipeworx data access, prediction markets, AI visibility, npm scanning, memory, and subscriptions—into one server. Each subfamily may be justified, but the combined surface is heavy and makes tool selection harder than the underlying tasks require.

Completeness4/5

The disease domain has query/disease/metadata for search-and-fetch read coverage, and the broader research side has lookup, grounded verification, deep research, entity profiles, comparisons, subscriptions, and memory lifecycle tools. Minor gaps exist (no direct tool to fetch pipeworx:// citation URIs, no disease browsing/pagination), but these are workable rather than blocking.

Resources